---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-089704"
form_type: "8-K"
ticker: "MRKR"
cik: "0001094038"
company_name: "Marker Therapeutics, Inc."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:14:48.372460+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Marker Therapeutics Q2 net loss narrows to $2.2M; reports positive MT-601 APOLLO data, receives $2M NIH grant

## Summary
- Net loss from continuing ops $2.2M vs $4.1M YoY; cash $7.8M expected to fund into Q4 2025.
- MT-601 APOLLO study shows objective responses in 3 of 3 lymphoma patients; no CRS or ICANS observed.
- Awarded $2M NIH SBIR grant to support MT-601 lymphoma trial.
- MT-401-OTS IND cleared for AML/MDS; clinical program initiation expected Q4 2024.
- R&D expenses $2.3M (flat); G&A decreased to $1.1M from $2.5M YoY.

## SEC filing metadata
- accession: 0001104659-24-089704
- form_type: 8-K
- ticker: MRKR
- cik: 0001094038
- company_name: Marker Therapeutics, Inc.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1094038/000110465924089704/0001104659-24-089704-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1094038/000110465924089704/tm2421372d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-089704
- JSON: https://secwatch.observer/filing/0001104659-24-089704.json
- Plain text: https://secwatch.observer/filing/0001104659-24-089704.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.